Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that Dendreon's Provenge, a dendritic-based vaccine, is the first vaccine therapy for prostate cancer shown to extend survival. The new Pharmacor study entitled Prostate Cancer finds that Provenge has demonstrated an improvement in time to disease progression among patients with less aggressive advanced tumors, and it has a favorable toxicity profile compared with that of docetaxel, the standard of care in this setting.
The study also finds that a reduction of reimbursement rates for hormone therapy will constrain the prostate cancer drug market. The 2004 Medicare Prescription Drug, Improvement, and Modernization Act is lowering the standard reimbursement rate for office-administered leuprolide and goserelin.
"A reduction in Medicare reimbursement rates will reduce U.S. oncologists' financial incentive to prescribe hormone therapy to patients with early-stage disease prior to radical treatment, a U.S.-specific practice for which no evidence base exists," said Mary Fletcher-Louis, analyst at Decision Resources. "This development will ensure that only men with high-risk early- stage prostate cancer receive hormone treatment."
Side Effects of Hormonal Therapies for Prostate Cancer
Although side effects of hormonal therapies are mild by comparison with cytotoxics, the long duration of use (often several years), makes these side effects onerous. Hormonal therapies cause loss of bone mineral density, hot flashes, sexual dysfunction, and gynecomastia (excessive development of mammary glands)--lessening patients' sense of well-being and causing depression.
About Pharmacor from Decision Resources
Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.
About Decision Resources
Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 email@example.com
SOURCE: Decision Resources, Inc.
CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
Web site: http://www.decisionresources.com/